Literature DB >> 11714771

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.

A Hombach1, A Wieczarkowiecz, T Marquardt, C Heuser, L Usai, C Pohl, B Seliger, H Abken.   

Abstract

Recombinant immunoreceptors with specificity for the carcinoembryonic Ag (CEA) can redirect grafted T cells to a MHC/Ag-independent antitumor response. To analyze receptor-mediated cellular activation in the context of CD28 costimulation, we generated: 1) CEA+ colorectal tumor cells that express simultaneously B7-1 and B7-2, and 2) CEA-specific immunoreceptors that harbor intracellularly the signaling moities either of CD28 (BW431/26-scFv-Fc-CD28), CD3zeta (BW431/26-scFv-Fc-CD3zeta), or FcepsilonRIgamma (BW431/26-scFv-Fc-gamma). By retroviral gene transfer, we grafted activated T cells from the peripheral blood with these immunoreceptors. T cells that express the FcepsilonRIgamma or CD3zeta signaling receptor lysed specifically CEA+ tumor cells and secreted high amounts of IFN-gamma upon receptor cross-linking, whereas anti-CEA-CD28 receptor-grafted T cells did not, indicating that CD28 signaling alone is not sufficient for efficient T cell activation. CD28 costimulation did not affect cytolysis by T cells equipped with gamma- or zeta-signaling receptors, but enhanced both IFN-gamma secretion and proliferation. CD28 costimulation, however, was required for efficient IL-2 secretion of anti-CEA-gamma receptor-grafted T cells. Both purified CD4+ and CD8+ T cells grafted with immunoreceptors required CD28 costimulation for complete T cell activation. We integrated both CD28 and CD3zeta signaling domains into one combined immunoreceptor molecule (BW431/26-scFv-Fc-CD28/CD3zeta) with dual signaling properties. T cells grafted with the combined CD28/CD3zeta signaling receptor secreted high amounts of IL-2 upon Ag binding without exogenous B7/CD28 costimulation, demonstrating that both MHC-independent cellular activation and CD28 costimulation for complete T cell activation can be delivered by one recombinant receptor molecule.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714771     DOI: 10.4049/jimmunol.167.11.6123

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  104 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

3.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

4.  Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

Review 5.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

6.  Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.

Authors:  Mahesh Jonnalagadda; Armen Mardiros; Ryan Urak; Xiuli Wang; Lauren J Hoffman; Alyssa Bernanke; Wen-Chung Chang; William Bretzlaff; Renate Starr; Saul Priceman; Julie R Ostberg; Stephen J Forman; Christine E Brown
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

7.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 8.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.

Authors:  Lei Jiang; Kang Yu; Jimei DU; Wuhua Ni; Yixiang Han; Shenmeng Gao; Haiying Li; Jianbo Wu; Yihu Zheng; Yingxia Tan
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

Review 10.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.